Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphomaChristos Vaklavas, Ruby F Meredith, Sui Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administrationAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2013
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patientsRuby F Meredith, Julien Torgue, Michael T Azure, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Medical Physics|November 6, 2014
End-to-end test of spatial accuracy in Gamma Knife treatments for trigeminal neuralgiaIvan A Brezovich, Xingen Wu, Jun Duan, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 regionBuck E Rogers, Peter L Roberson, Sui Shen, et al.
Frontiers in Cellular and Infection Microbiology|October 1, 2025
Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspectiveXing-Yu Luo, Wei-Bin Huang, Chuang-Hui Lu, et al.
Medical Physics|January 10, 2004
Validation of target volume and position in respiratory gated CT planning and treatmentSui Shen, Jun Duan, John B Fiveash, et al.
Cureus|July 18, 2020
Reduced Margin Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung CancersMayank Patel, Tyler Colvin, Robert Spencer Kirkland, et al.
American Journal of Cancer Research|October 13, 2022
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trialsXiaoning Guo, Xiaohui Wang, Sui Shen, et al.
Pageof 8